

Supplementary Figure S7. Subgroup analysis of confirmed ORR by tTMB for (A) durvalumab plus EP versus EP and (B) durvalumab plus tremelimumab plus EP versus EP. In each panel, the shaded band shows the confidence interval for the ITT population; circle sizes are proportional to the number of responses. BEP, biomarker-evaluable population; CI, confidence interval; D, durvalumab; EP, platinum-etoposide; ITT, intention-to-treat; mut/Mb, mutations per megabase; ORR, objective response rate; T, tremelimumab; tTMB, tissue tumor mutational burden.

